Analysis of botulinum toxin type A in the treatment of chronic migraine: a report of 47 cases

doi:10.3877/cma.j.issn.2095-123X.2021.01.003

Abstract

Abstract:

Objective

To study the therapeutic effect of botulinum toxin serotype A (BoNTA) in the treatment of chronic migraine (CM).

Methods

A retrospective analysis was performed on 47 patients with CM admitted to the Department of Neurosurgery, Chengdu 363 Hospital from June 2018 to June 2019. All patients were treated with BoNTA. The severity of pain and the number of pain episodes per month were compared by preoperative and postoperative questionnaires.

Results

The average pain incidence reported by the patients before operation was 12(9,16) times per month, but the average pain incidence reported by the patients after operation was reduced to 3(1,5) times per month. The mean pain score also decreased from 7(7,8) points before surgery to 1(1,5) points after injection. Eleven patients reported pain free after injection, 28 patients reported significant relief of pain, 3 patients reported effective relief of pain, and only 5 patients reported no significant postoperative improvement. The mean follow-up time was 11.06 months.

Conclusion

BoNTA is a feasible and promising treatment for CM.

Key words: Chronic migraine, Botulinum toxin serotype A, Questionnaires

Sisong Wang, Ji Ren, Jianping Xiong, Hongwei Zheng, Changping Chen, Huadong Sun, Yongjun Chen, Huan Zhang, Wen Feng, Haipeng Pan. Analysis of botulinum toxin type A in the treatment of chronic migraine: a report of 47 cases[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2021, 11(01): 9-13.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2021.01.003

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2021/V11/I01/9

Figures/Tables 1

References 24

[1]	李舜伟，李焰生，刘若卓.中国偏头痛诊断治疗指南[J].中国疼痛医学杂志, 2011, 17(2): 65-86.
[2]	中华医学会疼痛学分会头面痛学组，中国医师协会神经内科医师分会疼痛和感觉障碍专委会.中国偏头痛防治指南[J].中国疼痛医学杂志, 2016, 22(10): 721-727.
[3]	Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results[J]. Cephalalgia, 2015, 35(7): 563-578.
[4]	Headache classification committee of the International Headache Society(IHS) the international classification of headache disorders, 3rd edition[J]. Cephalalgia, 2018, 38(1): 1-211.
[5]	Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type a as a migraine preventive treatment. For the botox migraine clinical research group[J]. Headache, 2000, 40(6): 445-450.
[6]	Blumenfeld AM, Silberstein SD, Dodick DW, et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes[J]. Headache, 2017, 57(5): 766-777.
[7]	GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the global burden of disease study 2016[J]. Lancet Neurol, 2019, 18(5): 459-480.
[8]	Dodick DW, Loder EW, Manack Adams A, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study[J]. Headache, 2016, 56(5): 821-834.
[9]	Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis[J]. Cephalalgia, 2017, 37(5): 470-485.
[10]	Gu S, Jin R. Assembly and function of the botulinum neurotoxin progenitor complex[J]. Curr Top Microbiol Immunol, 2013, 364: 21-44.
[11]	Blumenfeld AM, Stark RJ, Freeman MC, et al. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study[J]. J Headache Pain, 2018, 5, 19(1): 13.
[12]	Restani L, Antonucci F, Gianfranceschi L, et al. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A)[J]. J Neurosci, 2011, 31(44): 15650-15659.
[13]	Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy[J]. Headache, 2004, 44(1): 35-42; discussion 42-43.
[14]	Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain[J]. Pain, 2004, 107(1-2): 125-133.
[15]	Drinovac V, Bach-Rojecky L, Lacković Z. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor[J]. J Neural Transm (Vienna), 2014, 121(6): 665-669.
[16]	Drinovac Vlah V, Bach-Rojecky L, Lacković Z. Antinociceptive action of botulinum toxin type A in carrageenan-induced mirror pain[J]. J Neural Transm (Vienna), 2016, 123(12): 1403-1413.
[17]	Voller B, Sycha T, Gustorff B, et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A[J]. Neurology, 2003, 61(7): 940-944.
[18]	Burstein R, Zhang X, Levy D, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains[J]. Cephalalgia, 2014, 34(11): 853-869.
[19]	Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors[J]. J Neurosci, 2017, 37(44): 10587-10596.
[20]	Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program[J]. Headache, 2010, 50(9): 1406-1418.
[21]	Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies[J]. Headache, 2015, 55(1): 3-20.
[22]	Masters-Israilov A, Robbins MS. OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine[J]. Headache, 2019, 59(10): 1753-1761.
[23]	Freund B, Rao A. Efficacy of botulinum toxin in tension-type headaches: a systematic review of the literature[J]. Pain Pract, 2019, 19(5): 541-551.
[24]	Yuan H, Silberstein SD. The use of botulinum toxin in the management of headache disorders[J]. Handb Exp Pharmacol, 2021, 263: 227-249.

Please choose a citation manager

Content to export